BridgeBio (BBIO) CAO Apuli Maricel Sells 2,000 Shares

What Happened
Apuli Maricel, Chief Accounting Officer of BridgeBio Pharma, sold 2,000 shares of BBIO in an open-market/private sale on July 30, 2026, at $80.06 per share, generating $160,120 in proceeds. The filing indicates the sale was executed pursuant to a Rule 10b5-1 sales plan.

Key Details

• Transaction date and price: 2026-07-30 — 2,000 shares sold at $80.06 each.
• Total proceeds: $160,120.
• Method: Open market or private sale (reported as a sale, code "S").
• Footnote: Transaction effected under a Rule 10b5-1 sales plan adopted September 8, 2025.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Timeliness: Form 4 filed on 2026-08-03; this meets the standard two-business-day filing requirement (not reported as late).

Context
A sale under a prearranged 10b5-1 plan is typically a routine disposition and does not necessarily reflect the insider’s current view of the company. For retail investors, purchases often carry more direct informational weight than routine sales; this single CAO sale for about $160k should be considered alongside other insider activity and company news.